
Background Cardiovascular disease remains the leading cause of death worldwide, resulting in an increasing demand for long-term treatment options for patients with end-stage heart failure. While heart transplantation is the gold standard, donor organ shortage continues to be a major limitation, particularly in countries with opt-in consent systems. Summary Durable mechanical circulatory support (dMCS) devices have emerged as a critical therapy for patients with advanced heart failure, either as a bridge to transplantation or as destination therapy. Technological innovations over recent decades have transitioned from pulsatile to continuous-flow systems, with the HeartMate 3 currently representing the only long-term left ventricular support, due to its superior hemocompatibility, clinical outcomes, and full magnetic levitation. However, limitations persist, especially regarding right-sided and biventricular support, driveline infections, and patient quality of life. This review provides a comprehensive overview of both currently approved and investigational dMCS devices, highlighting key engineering features, hemocompatibility advancements, and the status of ongoing clinical trials. Emerging devices such as the Corheart 6, BrioVAD, EvaHeart 2, CorWave, FlowMaker, and TorVAD aim to enhance physiologic support, minimize shear stress, and enable full implantability. Additionally, novel concepts for biventricular and total heart replacement, including BerlinHeart Excor, reBEAT, DuoCor BiVAS, SynCardia, Emperor and BiVACOR are discussed. Key Messages •HeartMate 3 remains the only approved LVAD in Europe following HVAD withdrawal. •Next-generation devices aim to improve hemocompatibility, reduce complications, and support full implantability. •Options for biventricular or right heart failure remain limited, but novel concepts are emerging.
Introduction: Percutaneous isolated hepatic perfusion enables regional delivery of high-dose chemotherapy while limiting systemic exposure through extracorporeal drug removal. In current clinical practice, this is achieved by the use of activated charcoal-based filtration systems, which are limited by finite adsorption capacity and non-selective binding. Hemodialysis filters may provide a membrane-based alternative for extracorporeal drug elimination. This study compared the efficacy of both systems for cisplatin removal. Methods: An isolated perfused porcine liver model was used. Livers were randomized into charcoal filtration, hemodialysis filtration, or control groups (n=5 per group). Cisplatin was administered into the hepatic circulation, and drug removal was performed according to group allocation. Cisplatin concentrations, liver injury markers, bile production, and blood cell counts were assessed. Results: Hemodialysis filters achieved significantly greater cisplatin clearance compared with activated charcoal filters, with sustained differences over time. Liver injury markers and bile production did not differ between groups. Blood cell counts revealed no relevant treatment effects. Conclusion: Hemodialysis filters improve cisplatin removal without affecting liver injury markers or blood cell counts in this experimental model.
Introduction: Intrapancreatic perineural invasion (IPNI) was a poor prognostic factor in pancreatic ductal adenocarcinoma (PDAC), but few studies quantified the severity of IPNI. Additionally, there was an absence of non-invasive tool to predicted IPNI. Methods: Patients who underwent radical pancreatectomy betweem 2018 and 2022 were enrolled. Severity of IPNI was assessed via binary classification, numeration, and neural invasion (NI) severity score. Cox regression analysis was performed to clarify the relationship between IPNI and prognosis. Clinical data, artificial intelligence (AI) , and radiomics were used to develop predictive models, evaluated by receiver operating characteristics (ROC) curve and decision curve analysis (DCA). Kaplan-Meier analysis confirmed the model's clinical utility. Results: A total of 192 patients were enrolled and rate of IPNI was 93.8%. Cox regression analysis and ROC curve indicated NI severity score>10.5 was responsible for poor prognosis (p<0.05). Further analysis indicated the AI model had better performance in predicting NI severity score>10.5 in both training set (clinical model AUC=0.66, AI model AUC=0.85, radiomics model AUC=0.81) and validation set (clinical model AUC=0.74, AI model AUC=0.84, radiomics model AUC=0.73). According to the predictive results of AI model, patient with NI severity score>10.5 had decreased recurrence free survival(RFS) and overall survival(OS) in training set (RFS 12months vs. 24 months, p=0.002; OS 24 months vs. 35 months, p=0.024) and validation set (RFS 8 months vs. 16 months, p=0.03; OS 25 months vs. 36 months, p=0.04). Conclusions: NI severity score >10.5 predicted poor PDAC prognosis, and AI was an useful tool to predict it.
BACKGROUND:Several techniques have been designed to increase the size of the future liver rem-nant (FLR) prior to liver resection. This experimental study in pigs builds on our previous rat study, in which we demonstrated that portal vein ligation (PVL) combined with radiofrequency ablation (RFA)-termed Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatec-tomy (ARAPS)-induces accelerated future liver remnant (FLR) growth comparable to the ALPPS procedure. METHODS:Eighteen female pigs were randomly assigned to PVL, ARAPS, or as controls. On post operative day (POD) 0, blood samples were collected, and 18F-FDGal PET and ceCT scans were conducted. Intervention pigs underwent either PVL or ARAPS. On POD 7, intervention pigs were re-evaluated with blood samples and 18F-FDGal PET/ceCT scans. Liver biopsies were obtained from the devascularized liver on POD 0 and POD 7, and from the FLR on POD 7 for histological analysis and growth rate kinetics. Control pigs were assessed only on POD 0. RESULT:The median FLR volume increase was comparable between the two groups at POD 7 (p=0.52). Further a shift in the distribution of liver function between the FLR and the deportalized liver was observed at POD 7 without significant difference in 18F-FDGal accumulation (percentage of injected dose in the liver) between groups (p = 0.15). The biochemical liver response did not differ between groups at any time. Additionally, no differences in hepatocyte morphology were found at POD 0. At POD 7, increased hepatocyte hypertrophy (p<0.004) and proliferation (p<0.001) were found in the ARAPS group compared to PVL. The regenerative capacity was most prominent in the FLR compared to the deportalized liver. CONCLUSION:ARAPS may enhance the proliferative response of the FLR compared to PVL alone, while still maintaining liver function comparable to PVL.
BACKGROUND:Cardiogenic shock (CS) remains a leading cause of early death in acute cardiac care, with 30-day mortality frequently approaching 40-50% despite advances in revascularization and critical care pathways. Contemporary CS management has progressed through standardized definitions, staging systems, and phenotyping frameworks that support earlier recognition and a more disciplined escalation strategy. However, evidence-based therapies that consistently reduce mortality remain limited, and device-related complications and heterogeneous etiologies continue to constrain outcome gains. SUMMARY:Temporary mechanical circulatory support (tMCS) provides rapid hemodynamic stabilization, augments end-organ perfusion, and enables time for revascularization, recovery, durable left ventricular assist device (LVAD) implantation, or transplantation. The major tMCS modalities used in current practice include intra-aortic balloon pump, percutaneous microaxial flow pumps, left atrial-to-arterial bypass devices, and venoarterial extracorporeal membrane oxygenation (VA-ECMO), with dedicated right-sided support strategies for right ventricular failure. Selection should be driven by (i) shock stage and trajectory, (ii) dominant ventricular lesion (LV, RV, or biventricular), (iii) oxygenation need, (iv) anatomical constraints and access options, and (v) intent (bridge to decision, recovery, durable LVAD, or transplant). Randomized evidence supports immediate culprit lesion revascularization for myocardial AMI-CS and suggests benefit from routine microaxial flow pump support in carefully selected AMI-CS patients without major hypoxic brain injury risk, albeit at the cost of higher bleeding and limb ischemia. In contrast, routine early VA-ECMO in infarct-related CS has not demonstrated mortality benefit in randomized trials and is associated with increased complications; therefore, VA-ECMO should be reserved for selected phenotypes, including refractory shock with severe hypoxemia, profound biventricular failure, or circulatory collapse, and should be embedded within an explicit unloading, anticoagulation, limb perfusion, and weaning protocol. KEY MESSAGE:tMCS implantation and management should be based on cardiogenic severity and phenotype.